Remodulin and Tamiflu drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Remodulin (treprostinil sodium) and Tamiflu (oseltamivir phosphate). Common drug interactions include premature delivery among females.

The phase IV clinical study analyzes what interactions people have when they take Remodulin and Tamiflu. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Remodulin?

Remodulin has active ingredients of treprostinil sodium. It is often used in primary pulmonary hypertension. eHealthMe is studying from 55,843 Remodulin users. Check the latest studies of Remodulin.

What is Tamiflu?

Tamiflu has active ingredients of oseltamivir phosphate. It is often used in the flu. eHealthMe is studying from 22,209 Tamiflu users. Check the latest studies of Tamiflu.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 20, 2026

19 people who take Remodulin and Tamiflu together, and have interactions are studied.

Remodulin and Tamiflu drug interactions.

What are the common drug interactions of Remodulin and Tamiflu, by gender? *:

female:

Premature delivery
Dyspnoea (difficult or laboured respiration)
Cough
Device dislocation
Dizziness
Electrolyte imbalance
Headache (pain in head)
Hypervolaemia (abnormally increased volume of blood)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Hypotension (abnormally low blood pressure)

male:

n/a

What are the common drug interactions of Remodulin and Tamiflu, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Death

20-29:

Maternal exposure during pregnancy (use of substance during pregnancy)
Premature delivery

30-39:

n/a

40-49:

Nausea (feeling of having an urge to vomit)
Pain
Pain in extremity
Pulmonary hypertension (increase in blood pressure in the lung artery)
Pyrexia (fever)
Vomiting
Abdominal pain
Arthralgia (joint pain)
Chest pain
Decreased appetite

50-59:

n/a

60+:

Abdominal pain upper
Nasopharyngitis (inflammation of the nasopharynx)
Pneumonia

What are the existing conditions these people have? *

Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 4 people, 21.05%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 3 people, 15.79%
H1n1 Influenza (flu (influenza), which is caused by virus influenza a (h1n1)): 3 people, 15.79%
Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 2 people, 10.53%
Epidural Anaesthesia: 2 people, 10.53%
Anaesthesia: 2 people, 10.53%
Portal Hypertension (increase in the blood pressure within a system of veins called the portal venous system): 1 person, 5.26%
Maternal Exposure During Pregnancy (use of substance during pregnancy): 1 person, 5.26%
Hypotension (abnormally low blood pressure): 1 person, 5.26%
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Remodulin and Tamiflu?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously